Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lung disease
Biotech
Daiichi-Merck ph. 3 ADC program on pause after patient deaths
Daiichi and Merck’s phase 3 program for I-DXd has been hit with a hold after an unexpected number of deaths occurred.
Gabrielle Masson
Dec 18, 2025 11:22am
Thermo Fisher launches biopsy test to assess lung rejection risk
Oct 9, 2025 10:50am
aTyr flunks phase 3 lung disease trial, deflating stock
Sep 15, 2025 9:56am
Wave reports AATD win, but investors lukewarm
Sep 3, 2025 3:00pm
PureTech creates Celea to develop promising lung disease drug
Aug 12, 2025 10:46am
Expedition inks $645M Fosun deal to bring China asset to US
Aug 11, 2025 11:06am
